The product was safe and effective after 4 weeks of topical use, specifically on patients with darker skin types.

Compared to untreated patients, dupilumab-treated women showed no increased risk for spontaneous abortion, gestational diabetes, or hypertensive disorders.

A new case report demonstrated the JAK inhibitor’s efficacy at improving disease severity up to 6 months.

After fine-tuning, the VGG16 convolutional neural network outperformed other deep learning models in 2 of 3 key classification tasks.

Alphyn Biologics has dosed the first patient in a global phase 2b trial of zabalafin hydrogel for mild to moderate atopic dermatitis.

Dermatology Times' Editor in Chief Christopher Bunick, MD, PhD, discusses patient safety in the wake of AAD 2025, focusing on BPO recalls, corticosteroid risks, and JAK inhibitor innovations.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Patients reported the face, neck, and inner arms as the most affected body regions before treatment.

Researchers conducted a comprehensive review of ACD, detailing the condition’s epidemiology, pathophysiology, clinical manifestations, diagnostic approaches, and therapeutic options.

The guide prepares students to critically engage with AI tools and understand their real-world implications.

Long-pulsed KTP laser showed promise as a safe, effective alternative to PDL for treating port-wine birthmarks over 3 years.

Tofacitinib showed promise for easing itch and skin symptoms in prurigo nodularis, though effects may lessen over time.

Explore key takeaways from AAD 2025, rosacea insights, psoriasis updates, and expert interviews in the latest issue of Dermatology Times.

The method was safe and effective with high patient satisfaction rates 4 weeks post-injection.

Explore the top headlines of the week including insights on pandemic risks, weight loss medications, and more.

Test your knowledge of key words and terms associated with dermatology news from the previous week.

In case you missed it, this week we had news about pregnancy-related skin changes, art in clinical spaces, Allergan's upcoming skin quality index, and more.

This week, we feature top articles from our sister publications on the future of health care, FDA approvals, and more.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Allergan’s latest initiative hopes to empower both patients and clinicians while advancing industry standards, according to Sherket Peterson, PhD.

A cross-sectional survey revealed that many patients with HS are dissatisfied with treatment options, with gaps in knowledge about FDA-approved therapies.

The study found dupilumab-treated patients had the highest probability of remaining infection-free over 52 weeks.

Sherket Peterson, PhD, spoke to Dermatology Times about Allergan’s recent research and plan to launch a universal skin quality index.

Studies show that exposure to meaningful artwork can lower blood pressure and enhance mental clarity in patients.

Tremfya is the first IL-23 inhibitor to significantly improve both symptoms and structural damage in active psoriatic arthritis.